Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: Results of multicenter, randomized, double-blind comparative study

Surgical Infections

Volumn 6, Issue 3, 2005, Pages 269-282

  Fabian, Timothy C ^a   File Jr , Thomas M ^b   Embil, John M ^c   Krige, Jacobus E J ^d   Klein, Stanley ^e   Rose, Andrea ^f   Melnick, David ^f   Soto, Norberto E ^f   Abbas, Mujahed ^g   Adler, David ^g   Bacon, Alfred ^g   Barbaro, Daniel ^g   Barr, Lonson ^g   Becker, Professor ^g   Bellemare, Jean Francois ^g   Berkowitz, Kevin ^g   Berman, Steven ^g   Brill, Leon ^g   Bush, Larry ^g   Caplan, Ellis ^g   Choudhury, Shanana ^g   Christou, Nicolas ^g   Davies, Mark ^g   DeMarini, Thomas ^g   Desai, Y ^g   Dickey, Thomas ^g   Dryjski, Maciej ^g   Eron, Lawrence ^g   Falanga, Vincent ^g   Flint, Lewis ^g   Flynn, William ^g   Gareca, Marcelo ^g   Gezon, John ^g   Ghimenton, Fernando ^g   Glickman, Marc H ^g   Golin, Faldir ^g   Graham, Donald ^g   Hampton, R Moss ^g   Harding, Godfrey ^g   Harin, Stuart ^g   Harrison, Mark ^g   Ho, Hoi ^g   Hoffman, Wendall ^g   Hunt, John ^g   Irizarry, Lourdes ^g   Jauregui, Luis ^g   Khayr, Walid ^g   Kingman, Robert ^g   Levine, Donald ^g   Libman, Michael ^g   Lotfi, Carlos ^g   Lucasti, Christopher ^g   Luterman, Arnold ^g   Mazuski, John ^g   McIntyre, Robert ^g   McMillian, Michael ^g   Mersey, James H ^g   Miller, Miller A ^g   Miller, Preston ^g   Moran, Gregory ^g   Mushinsky Tralles, Ann ^g   Murray, James ^g   Natalino, Michael ^g   Nautiyal, Preeti ^g   Pien, Frances ^g   Quick, Rhonda ^g   Ramirez, Ramon ^g   Reid, Karlene ^g   Reiter, William ^g   Richardt, Charles ^g   Rogers, Selwyn ^g   Rohlf, Jane ^g   Royall, Steven ^g   Schrock, Christian ^g   Schwartz, Robert ^g   Sharpiro, Marc J ^g   Sioson, Priscilla ^g   Somberg, Lewis Brain ^g   Stone, Judy ^g   Straling, Carlos ^g   Tapscott, William ^g   Tun, Fabian ^g   Turner, William ^g   van Zyl, Louis ^g   Weireter, Leonard ^g   Wilson, Samuel Eric ^g   Wright, Neilson ^g   Young, Kim ^g   Zervos, Marcus ^g   Zellner, Stephen ^g   more..

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f ASTRAZENECA   (United Kingdom)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; METICILLIN; OXACILLIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM CULTURE; CELLULITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SKIN ABSCESS; SKIN INFECTION; SKIN STRUCTURE; TREATMENT OUTCOME; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; BACTERIA, ANAEROBIC; CILASTATIN; DOUBLE-BLIND METHOD; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; IMIPENEM; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 27844468556     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.269     Document Type: Article

References (23)

1. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63:1459-1480.
2. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621-1642.
3. Rennie RP, Jones RN, Mutnick AH, and the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45:287-293.
4. Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406-419.
5. Colsky AS, Kirsner RS, Kerdel FA. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol 1998;134:1006-1009.
6. Sader HS, Jones RN, Silva JB, The SENTRY Participants Group (Latin America). Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 2002;44:281-288.
7. Mutnick AH, Turner PJ, Jones RN. Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC program (1997-2001). J Chemother 2002;14:253-258.
8. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: Results from the European MYSTIC study group. Clin Microbiol Infect 2003;9:980-983.
9. Turner PJ, Greenhalgh JM, the MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 2003;9:563-567.
10. Unal S, Masterton R, Goossens H. Bacteraemia in Europe - Antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 2004;23:155-163.
11. Greenhalgh JM, Edwards JR. A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics. Clin Microbiol Infect 1997;3:S20-S31.
12. Hurst M, Lamb HM. Meropenem: A review of its use in patients in intensive care. Drugs 2000;59:653-680.
13. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997;28:157-163.
14. Ednie LM, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother 2002;50:101-105.
15. Pfaller MA, Jones RN, for the MYSTIC Study Group (Americas). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000;46:25-37.
16. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: Report and analysis of trends for 1997-2000. Clin Infect Dis 2002;35:S126-S134.
17. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
18. Maglio D, Teng R, Thyrum PT, et al. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother 2003;47:1771-1773.
19. NCCLS (National Committee for Clinical Laboratory Standards). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed., approved standard. M7-A5. Wayne, PA: NCCLS, 2000.
20. NCCLS. Performance standards for antimicrobial disk susceptibility tests, 7th ed., approved standards. M2-A7. Wayne, PA: NCCLS. 2000.
21. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed., approved standards. M11-A5. Wayne, PA: NCCLS, 2001.
22. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52:i3-17.
23. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.